Q3 2025 · 13F-HR
GREAT POINT PARTNERS LLCholdings as filed
Filed 2025-11-14 · accession 0001814554-25-000164
$242.5M
Reported value
30
Positions
2025-09-30
Period end
The Brief · GREAT POINT PARTNERS LLC · Q3 2025
AI · grounded in 13F
GREAT POINT PARTNERS LLC established a new position in NKTR worth $17.07M. The fund also opened new stakes in SLNO for $15.21M and ASNDUSD for $14.91M. On the sell side, the fund closed its position in AKBA, reducing exposure by $7.23M. Other notable exits included EOLS and ACLXGBX.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $23.1M | 9.53% | 1,700,000 | Common | SHARED |
| 76200L309 | RZLT | REZOLUTE INC COM NEW | $23.0M | 9.50% | 2,451,809 | Common | SHARED |
| 640268306 | NKTR | NEKTAR THERAPEUTICS COM NEW | $17.1M | 7.04% | 300,000 | Common | SHARED |
| G9TY5A101 | ZURA | ZURA BIO LTD CLASS A ORD SHS | $16.5M | 6.81% | 3,815,930 | Common | SHARED |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $15.2M | 6.27% | 225,000 | Common | SHARED |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S SPONSORED ADR | $14.9M | 6.15% | 75,000 | Common | SHARED |
| 00370M103 | ABVX | ABIVAX SA SPONSORED ADS | $12.7M | 5.25% | 150,000 | Common | SHARED |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $12.1M | 4.98% | 304,000 | Common | SHARED |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $10.5M | 4.31% | 265,803 | Common | SHARED |
| 23282W605 | CYTK | CYTOKINETICS INC COM NEW | $8.2M | 3.40% | 150,000 | Common | SHARED |
| 45258J102 | IMVT | IMMUNOVANT INC | $8.1M | 3.32% | 500,000 | Common | SHARED |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $8.0M | 3.31% | 200,000 | Common | SHARED |
| 64135M105 | NGNE | NEUROGENE INC | $7.7M | 3.19% | 446,814 | Common | SHARED |
| 29842P105 | EPRX | EUPRAXIA PHARMACEUTICALS INC | $7.1M | 2.92% | 1,200,000 | Common | SHARED |
| 91678A107 | UPB | UPSTREAM BIO INC | $5.6M | 2.33% | 300,000 | Common | SHARED |
| 008064206 | JBIO | JADE BIOSCIENCES INC COM NEW | $5.5M | 2.25% | 632,599 | Common | SHARED |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $5.2M | 2.16% | 80,000 | Common | SHARED |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $4.9M | 2.03% | 103,848 | Common | SHARED |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC COM SHS | $4.9M | 2.02% | 1,500,000 | Common | SHARED |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $4.5M | 1.87% | 4,683,711 | Common | SHARED |
| N69605108 | PHVS | PHARVARIS N V | $3.9M | 1.60% | 155,105 | Common | SHARED |
| 23306J309 | DBVT | DBV TECHNOLOGIES S A SPONSORED ADS | $3.8M | 1.56% | 378,594 | Common | SHARED |
| 52490G102 | LEGN | LEGEND BIOTECH CORP SPONSORED ADS | $3.7M | 1.53% | 113,460 | Common | SHARED |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $3.5M | 1.45% | 183,330 | Common | SHARED |
| 90466Y202 | UNCY | UNICYCIVE THERAPEUTICS INC COM NEW | $3.5M | 1.43% | 796,558 | Common | SHARED |
| 799566104 | SANA | SANA BIOTECHNOLOGY INC | $2.5M | 1.02% | 700,000 | Common | SHARED |
| 00091E109 | ABSI | ABSCI CORPORATION | $2.4M | 1.00% | 796,438 | Common | SHARED |
| 413197104 | HRMY | HRMY 10/17/2025 40 Call | $2.3M | 0.97% | 85,000 | CALL | SHARED |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $1.3M | 0.52% | 850,000 | Common | SHARED |
| 14070B309 | CAPR | CAPR 12/19/2025 7.5 Put | $632,317 | 0.26% | 87,700 | PUT | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.